Moderna Inc. ($MRNA) Stock Forecast: Down 6.2% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its innovative mRNA technology, notably demonstrated through its COVID-19 vaccine. The company is diversifying its portfolio beyond infectious diseases, focusing on areas like oncology and flu vaccines.

Why is Moderna Inc. going down?

MRNA stock is down 6.2% on Mar 3, 2026 18:40

• The decline in Moderna's stock today is possibly due to investors taking profits following a period of successful performance.
• Merck's notable revenue growth fueled by Keytruda, a competitor PD-1 inhibitor, might have sparked concerns about potential competition for Moderna in the immuno-oncology sector.
• The proposed stock offering by MAIA Biotechnology to finance trials could have affected Moderna's stock price, as investors may be wary of potential dilution in the biotech industry.
• Despite optimistic outlooks from analysts and advancements in its pipeline, general market sentiment regarding regulatory approvals and market acceptance of Moderna's mRNA-based vaccines may be influencing the stock's movements.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?

Merck's Keytruda, a leading PD-1 inhibitor, accounted for 55% of the company's pharmaceutical sales in 2025, reaching $31.7 billion. Merck anticipates continued growth for Keytruda until its patent exclusivity ends in 2028, with peak sales projected at $35 billion. To ensure long-term growth beyond Keytruda's exclusivity, Merck is reorganizing its Human Health segment and developing new immuno-oncology combinations and a personalized mRNA-based cancer vaccine.

https://www.tradingview.com/news/zacks:6b4379a1d094b:0-merck-s-keytruda-drives-its-2025-revenue-surge-what-s-ahead/

Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Moderna (MRNA)

Three analysts have issued bullish sentiments on healthcare stocks Nyxoah (NYXH), Moderna (MRNA), and Disc Medicine (IRON). Piper Sandler maintained Buy ratings on Nyxoah with a $9.00 price target and Moderna with a $69.00 price target. Stifel Nicolaus also maintained a Buy rating on Disc Medicine with a $111.00 price target.

https://www.theglobeandmail.com/investing/markets/stocks/IRON/pressreleases/531000/analysts-are-bullish-on-these-healthcare-stocks-nyxoah-nyxh-moderna-mrna/

Should You Listen to Billionaires to Buy Moderna Stock in 2026?

Moderna is transitioning from a reliance on its COVID-19 vaccine to a more diversified business model, including RSV and developing flu vaccines, alongside longer-term oncology programs. Despite past stock declines, recent positive pipeline developments and the engagement of billionaire investors suggest an improved risk/reward profile for MRNA in 2026. However, significant risks remain concerning regulatory approvals, market adoption, and the broader viability of its mRNA platform beyond infectious diseases.

https://www.tradingkey.com/analysis/stocks/us-stocks/261639386-listen-billionaires-buy-moderna-stock-mrna-2026-tradingkey

Cancer immunotherapy developer MAIA plans stock sale to fund trials

MAIA Biotechnology has announced a proposed underwritten public offering of common stock and pre-funded warrants, with proceeds intended to fund clinical trials, working capital, and general corporate purposes. The offering, originating from an existing S-3 shelf registration, is subject to market conditions. Following the news, MAIA's stock price declined by 21.72%, reflecting a significant negative market reaction due to potential dilution for existing shareholders.

https://www.stocktitan.net/news/MAIA/maia-biotechnology-announces-proposed-underwritten-public-offering-2dhxiagwddvb.html

Moderna, Inc. (MRNA) Stock Analysis: Navigating Challenges with a Diverse Vaccine Pipeline

Moderna (MRNA) faces significant financial challenges, including negative P/E and free cash flow, despite its robust and diverse vaccine pipeline extending beyond COVID-19. Analyst ratings are mixed, indicating caution due to potential downsides, yet technical indicators suggest short-term bullish momentum. The company's strategic alliances and R&D in various therapeutic areas are key assets for future growth, but sustained success will depend on managing resources and continued innovation.

https://www.directorstalkinterviews.com/moderna-inc-mrna-stock-analysis-navigating-challenges-with-a-diverse-vaccine-pipeline/4121242334

Trending Today

Excelerate Energy ($EE) Stock Forecast: Down 5.2% Today

Circle Internet Group ($CRCL) Stock Forecast: Up 7.4% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Down 8.5% Today

Zillow Group Inc. ($Z) Stock Forecast: Up 5.1% Today

Harley-Davidson Inc. ($HOG) Stock Forecast: Up 5.4% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Down 5.3% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Down 5.9% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Down 5.4% Today

Schlumberger N.V. ($SLB) Stock Forecast: Down 5.2% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 5.0% Today

Moderna Inc. Price History

02.02.2026 - MRNA Stock was up 5.2%

• Moderna's stock saw an upward trajectory after receiving endorsement from the CHMP for its mCombriax COVID-19 and influenza combination vaccine. This favorable development, supported by promising Phase III study results, signifies a significant stride towards approval in the EU and potentially beyond.
• A price target increase by Piper Sandler for Moderna mirrors confidence in the company's vaccine portfolio, which includes upcoming milestones like the PDUFA date for the flu vaccine and Phase III melanoma data. Investors are reacting positively to the growth opportunities highlighted by Piper Sandler, despite ongoing safety concerns linked to mRNA technology.
• The positive trend in Moderna's stock stands in contrast to the challenges being tackled by other biotech firms such as Annovis Bio, CRISPR Therapeutics, and Alnylam Pharmaceuticals, as each navigates its distinct developments and regulatory environments.
• In summary, Moderna's bullish movement today is a result of favorable regulatory endorsements, advancements in its pipeline, and market enthusiasm surrounding its vaccine technologies, despite lingering safety considerations.

02.02.2026 - MRNA Stock was up 5.6%

• Moderna's stock rose after receiving a favorable opinion from the European Medicines Agency's drug review committee for its dual Covid-flu vaccine. This places Moderna at the forefront of the global competition for a combined vaccine.
• Concerns expressed by Pfizer's CEO regarding FDA leadership and internal disagreements on vaccine strategies may have indirectly benefitted Moderna, highlighting potential regulatory advantages for the company.
• Analysts have a positive view on Moderna's stock, increasing price targets and emphasizing its robust vaccine pipeline, contributing to investor confidence and the stock's upward movement.
• Moderna's strategic shift towards cancer and rare disease pipelines, in addition to potential regulatory approvals across various regions, showcases the company's diversification beyond Covid-19 vaccines, making it an appealing option for investors.

20.01.2026 - MRNA Stock was up 8.3%

• The positive momentum in MRK stock could be linked to an upgraded Buy rating from Deutsche Bank with an increased price target. This optimistic forecast on the company's growth prospects, disregarding concerns about the Keytruda patent cliff, likely bolstered investor confidence.
• Furthermore, the FDA's approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication affirmed Merck's market position, underscoring its dedication to developing groundbreaking treatments.
• Ongoing patent disputes and legal conflicts in the biotech sector, like BioNTech's lawsuit against Moderna for patent infringement regarding COVID shots, may have impacted market sentiment towards established players such as Merck, potentially generating heightened interest and investment in the company's stock.

03.02.2026 - MRNA Stock was down 6.3%

• Analysts are bullish on Moderna, maintaining Buy ratings and positive price targets, indicating long-term growth potential.
• The transition to a more diversified business model, including RSV and flu vaccines, has garnered investor interest, but concerns remain regarding regulatory approvals and market adoption.
• The decline in Moderna's stock price could be attributed to the negative market reaction to MAIA Biotechnology's stock sale announcement, raising concerns about potential dilution for existing shareholders.
• Despite positive news of Moderna's dual Covid-flu vaccine nearing EMA approval, regulatory hurdles in the US for other vaccines and shifting focus to different pipelines may have contributed to the bearish market movement.

23.01.2026 - MRNA Stock was up 6.0%

• Moderna experienced a strong bullish movement today due to multiple factors:
• Gilead Sciences' acquisition of Arcellx, focusing on CAR T-cell therapy, brought positive attention to the biotech sector and potentially increased investor confidence in similar companies like Moderna.
• The FDA's decision to review Moderna's mRNA flu vaccine and the initiation of the review for its investigational seasonal influenza vaccine submission (mRNA-1010) signaled progress and potential future revenue streams for the company.
• Despite facing legal challenges related to patent infringement and mixed financial results, including declining revenue, the positive developments with FDA reviews and vaccine submissions outweighed the concerns for investors.
• Telemark Asset Management LLC's significant acquisition of Moderna shares also indicated confidence in the company's future prospects, contributing to the bullish movement.

24.01.2026 - MRNA Stock was down 6.5%

• The bearish movement in MRNA's stock today is linked to concerns over potential FDA actions on mRNA vaccines, causing uncertainty and regulatory hurdles for the company's future vaccine developments.
• The negative revenue outlook and financial challenges may have led to investor caution and selling pressure on the stock.
• Despite recent positive updates, such as regulatory approvals and strategic agreements, the market sentiment appears to have been influenced more by broader challenges and uncertainties facing Moderna, resulting in the bearish movement in the stock today.

19.01.2026 - MRNA Stock was up 5.6%

• Merck & Co., Inc. (MRK) is a pharmaceutical company recognized for its innovative healthcare solutions. Today, the stock saw significant bullish movement in the market.
• MRK upgraded to a Buy rating by Deutsche Bank with a higher price target, noting undervaluation despite Keytruda patent cliff concerns.
• FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication strengthened investor confidence in the company's growth prospects.
• Positive developments regarding MRK outshined worries about the Keytruda patent cliff, leading to the stock's bullish market movement.
• Investor optimism towards MRK's future growth prospects and product portfolio expansion drove the market's positive reaction.

25.01.2026 - MRNA Stock was up 5.6%

• Despite concerns about Moderna's financial standing, the stock has shown a notable recovery in its share price, signaling growing investor confidence.
• Positive outlook in the options market for Moderna, evident by the majority of trades predicting favorable outcomes, aligns with the current upward trend of the stock.
• Moderna's recent announcement about the FDA's review of its new mRNA flu vaccine, following dispute resolutions, likely contributed to the optimistic market sentiment and stock price surge.
• Protalix Biotherapeutics' strong performance, reaching a new 52-week high, reflects the overall robustness in the pharmaceuticals and biotechnology sector, potentially bolstering investor trust in companies like Moderna.

18.01.2026 - MRNA Stock was up 9.5%

• Moderna faced setbacks in a patent dispute with Arbutus Biopharma, but the market remained bullish, indicating that investors are focusing more on the company's overall potential and developments in its vaccine pipeline.
• The FDA's decision to review Moderna's mRNA flu shot application, along with the positive results from the mid-stage trial of their combo flu/COVID vaccine, likely contributed to the bullish movement of the stock.
• Despite the ongoing legal challenges and regulatory hurdles, Moderna's innovative approach to vaccine development and the promising results of its trials seem to have instilled confidence in investors, driving the stock price up.

18.01.2026 - MRNA Stock was up 5.5%

• Optimism among investors was ignited by the FDA's decision to reassess Moderna's mRNA flu shot application after an initial rejection, potentially creating a new revenue source for the company.
• Despite uncertainties stemming from setbacks in the patent dispute with Arbutus Biopharma, investor focus on the flu vaccine review seemed to outweigh these concerns.
• Strong results from Moderna's combination flu/COVID vaccine trial further solidified investor confidence in the company's capabilities and future outlook, driving the bullish movement in stock price.
• Overall, market response to the FDA's review of Moderna's flu shot and encouraging vaccine trial outcomes indicates investor optimism about the company's ongoing success and innovation within the healthcare sector.

03.02.2026 - MRNA Stock was down 6.2%

• The decline in Moderna's stock today is possibly due to investors taking profits following a period of successful performance.
• Merck's notable revenue growth fueled by Keytruda, a competitor PD-1 inhibitor, might have sparked concerns about potential competition for Moderna in the immuno-oncology sector.
• The proposed stock offering by MAIA Biotechnology to finance trials could have affected Moderna's stock price, as investors may be wary of potential dilution in the biotech industry.
• Despite optimistic outlooks from analysts and advancements in its pipeline, general market sentiment regarding regulatory approvals and market acceptance of Moderna's mRNA-based vaccines may be influencing the stock's movements.

13.01.2026 - MRNA Stock was up 6.7%

• Moderna's stock experienced a bullish movement as the company exceeded fourth-quarter revenue expectations, driven by better-than-expected sales of its Covid vaccine.
• The positive outlook for Moderna can also be attributed to the overall market sentiment, with U.S. consumer prices rising less than anticipated, providing a boost to investor confidence.
• The increased capital injection into Jiuzi Holdings by multiple crypto investment institutions may have also contributed to a positive market sentiment, indirectly benefiting Moderna and other companies in the market.
• Analysts closely monitoring Moderna's performance amidst competition in the biotech space, particularly in the kidney disease portfolio and the expanding applications of its drugs, could have further fueled investor optimism in the stock.